Search research articles
Contact Us
Filters
Showing results (1-10 of 21) with videos related to
Page
of 3
Sort By:
Cancer Treatment Reviews
|
February 25, 2006
Taxanes in paediatric oncology: and now?
Nicolas André, Christophe Meille
The AAPS Journal
|
February 8, 2021
Translational Modeling of Anticancer Efficacy to Predict Clinical Outcomes in a First-in-Human Phase 1 Study of MDM2 Inhibitor HDM201
Nelson Guerreiro, Astrid Jullion, Stephane Ferretti, et al.
Clinical Pharmacokinetics
|
March 7, 2016
Revisiting Dosing Regimen Using Pharmacokinetic/Pharmacodynamic Mathematical Modeling: Densification and Intensification of Combination Cancer Therapy
Christophe Meille, Dominique Barbolosi, Joseph Ciccolini, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
|
February 18, 2014
Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration
Guillaume Baneyx, Neil Parrott, Christophe Meille, et al.
Journal of Pharmacological and Toxicological Methods
|
June 1, 2014
Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development
Antonello Caruso, Nicolas Frances, Christophe Meille, et al.
Breast Cancer Research and Treatment
|
March 23, 2016
Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patients
Emilie Hénin, Christophe Meille, Dominique Barbolosi, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
June 21, 2022
Contribution of machine learning to tumor growth inhibition modeling for hepatocellular carcinoma patients under Roblitinib (FGF401) drug treatment
Mélanie Wilbaux, David Demanse, Yi Gu, et al.
Cancer Chemotherapy and Pharmacology
|
August 2, 2014
Metronomics chemotherapy: time for computational decision support
Dominique Barbolosi, Joseph Ciccolini, Christophe Meille, et al.
BMC Cancer
|
April 21, 2016
A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol
Xavier Elharrar, Dominique Barbolosi, Joseph Ciccolini, et al.
Clinical Pharmacology and Therapeutics
|
September 22, 2022
Integration of Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy into Model-Informed Dose Selection in Oncology First-in-Human Study: A Case of Roblitinib (FGF401)
Mélanie Wilbaux, Shu Yang, Astrid Jullion, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 21) with videos related to
Sort By:
Page
of 3
Cancer Treatment Reviews
|
February 25, 2006
Taxanes in paediatric oncology: and now?
Nicolas André, Christophe Meille
The AAPS Journal
|
February 8, 2021
Translational Modeling of Anticancer Efficacy to Predict Clinical Outcomes in a First-in-Human Phase 1 Study of MDM2 Inhibitor HDM201
Nelson Guerreiro, Astrid Jullion, Stephane Ferretti, et al.
Clinical Pharmacokinetics
|
March 7, 2016
Revisiting Dosing Regimen Using Pharmacokinetic/Pharmacodynamic Mathematical Modeling: Densification and Intensification of Combination Cancer Therapy
Christophe Meille, Dominique Barbolosi, Joseph Ciccolini, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
|
February 18, 2014
Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration
Guillaume Baneyx, Neil Parrott, Christophe Meille, et al.
Journal of Pharmacological and Toxicological Methods
|
June 1, 2014
Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development
Antonello Caruso, Nicolas Frances, Christophe Meille, et al.
Breast Cancer Research and Treatment
|
March 23, 2016
Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patients
Emilie Hénin, Christophe Meille, Dominique Barbolosi, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
June 21, 2022
Contribution of machine learning to tumor growth inhibition modeling for hepatocellular carcinoma patients under Roblitinib (FGF401) drug treatment
Mélanie Wilbaux, David Demanse, Yi Gu, et al.
Cancer Chemotherapy and Pharmacology
|
August 2, 2014
Metronomics chemotherapy: time for computational decision support
Dominique Barbolosi, Joseph Ciccolini, Christophe Meille, et al.
BMC Cancer
|
April 21, 2016
A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol
Xavier Elharrar, Dominique Barbolosi, Joseph Ciccolini, et al.
Clinical Pharmacology and Therapeutics
|
September 22, 2022
Integration of Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy into Model-Informed Dose Selection in Oncology First-in-Human Study: A Case of Roblitinib (FGF401)
Mélanie Wilbaux, Shu Yang, Astrid Jullion, et al.
Page
of 3